Edgewise Therapeutics EWTX
$39.91 −$1.27 (-3.07%)
Market closed · Nov 22, 5:10 am ET · Last extended-hours $39.91 0.00%
Open$40.81
Prev close$41.17
Day range$39.71 – $41.41
Volume1.19M
Market cap$4.37B
P/E (TTM)4.8
Dividend yield–
EWTX Stock News
Headlines matching Edgewise Therapeutics or the EWTX ticker, most recent first.
- Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX) Positive
- RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $59
- Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
- H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $57
- Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $53 Positive
- Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)
- H.C. Wainwright Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $57
- H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45
- Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $55
- J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $60 Positive
- J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $60
- Guggenheim Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51 Positive
- Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $55 Positive
- Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51
- J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $53 Positive
No comments yet — be the first to weigh in on EWTX.
Sign in to join the discussion.